In previous studies, we have shown that some, but not all IOW-, intermediate-, and high-purity factor Vlll concentrates inhibit interleukin-2 (IL-2) secretion from phytohemagglutinin (PHA)-stimulated T lymphocytes. We now present evidence that this inhibitory action of concentrates is, at least in part, due to contamination with transforming growth factor-/3 (TGF-P). Originally identified in platelets, TGF-/3 is a 25-kD homodimer that has been shown to be a natural and potent inhibitor of many immunologic responses. Using a specific bioassay, we have measured TGF-B in various factor Vlll concentrates. While some concentrates contained substantial amounts of the cytokine, there was a wide variation in concentrations of TGF-/3 in different products. These lev-
BNORMALITIES IN immunologic parameters unrelated to human immunodeficiency virus (HIV) infection
have been observed in hemophiliac^."^ These include functional lymphocyte defects, such as impaired natural-killer cell activity: diminished lymphoproliferative responses to phytohemagglutinin (PHA),' which is associated with a decreased capacity of the cells to produce interleukin-2 (IL-2),3 B-cell dysfunction,6 deficient skin test responses to recall antigens or to dinitrochlorobenzene?~' and impaired monocyte chemotaxis and phagocytic f~n c t i o n .~.~ Attempts to explain these defects have focused on the possible detrimental effects of repeated infusions of factor VIII concentrates," because concentrates can contain large amounts of non-factor VI11 plasma proteins, and especially alloantigens, which may cause an antigen overload and impair the immune system. However, the mechanism and the agent(s) responsible for these abnormalities are still unclear. Impairment of lymphocyte and monocyte function on exposure to factor VIII concentrates has been demonstrated in Previous work in our laboratory and elsewhere showed that some factor VI11 and IX concentrates have a dose-dependent inhibitory effect on lymphocyte IL-2 secretion and proliferation.",12 This inhibitory effect was disparate and dependent on the product. We found no obvious relationship between inhibitory activity and purity or gross protein composition of the product, but factor VI11 itself was not responsible because products prepared by recombinant DNA technology or affinity purification procedures were totally noninhibitory." In a more recent study, we have shown that the inhibitory activity of some products on IL-2 secretion can be mainly attributed to a 200 kD macromolecular component. However, some other protein components may also mediate this effect, and some products contain a dialyzable low-molecular weight inhibitory substance, such as citrate, which is present in formulation buffers used for the manufacture of these prod~cts.'~ Because some factor VI11 concentrates inhibit IL-2 secretion from stimulated T cell^,'^.'^ it seemed logical to extend our previous studies to establish if factor VI11 concentrates could also cause inhibition of secretion and/or action of other cytokines. Although factor VI11 concentrates did not affect the biologic activity of interleukin-l (IL-1) or interleukin-6 (IL-6) (unpublished data, January 1993), the activity of other cytokines, such as interleukin-4 (IL-4) and interleukin-5 (IL-5) was considerably inhibited. Such varied effects of concentrates on cytokine activity seemed reminiscent of the biologic actions of transforming growth factor-@ (TGF-@).I6 Therefore, we analyzed different factor VI11 concentrates for the presence of this cytokine. Here, we present data that show the inhibitory effects on IL-2 secretion, as well as some related phenomena of factor VI11 concentrates, are mediated by TGF-P.
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-30000 - absorption (specific activity, -3,000 IU/mg protein before addition of an albumin stabilizer) consisted of SolvenVdetergent-treated J from BPL (Elstree, UK, 8SM); and pasteurized K from Armour Pharmaceuticals (Kankakee, L; Monoclate P).
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Cytokines. Recombinant human IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) were gifts of ScheringPlough Corp (Kenilworth, NJ). Recombinant human TGF-P1 was donated by R & D Systems (Minneapolis, MN) and Bristol-Myer Squibbs (Seattle, WA).
Origin and maintenance of cell lines. The human erythroleukemia cell line, TF-I, was a gift of Dr T. Kitamura, University of Tokyo (Tokyo, Japan)." This line was maintained at a density of IO4 to l@ cell/mL in RPMI 1640 medium containing 2 ng/mL recombinant human GM-CSF (rhGM-CSF), and 5% heat-inactivated fetal calf serum (FCS).
The human T-cell lymphoblastoid line, Jurkat, was maintained at a density of 1 O5 to 1 O6 cells/mL in RPMI 1640 containing 10% heatinactivated FCS.
The murine T-cell line, CTLL-2, was maintained at a density of approximately 2 X IO4 cells/mL in RPMI 1640 supplemented with 10% FCS and partially purified rat It-2 (15 to 20 IU/mL). The cultures were maintained on a 3-day feeding schedule." All cell lines and cultures were incubated at 37°C in a humidified atmosphere containing 5% COn.
Separation of peripheral blood mononuclear cells from whole blood Peripheral blood mononuclear cells (PBMCs) were separated from freshly collected heparinized blood by centrifugation over Histopaque-1077 (density, 1.077; Sigma, Poole, UK) at 4oog for 30 minutes. Mononuclear cells were removed from the interface, washed three times with RPMI 1640, and immediately used for experiments.
Effects of factor VI11 concentrates on IL-2 secretion using stimulated Jurkat cells or PBMCs. For stimulation of IL-2 secretion, cells were resuspended at 2 X 106/mL in RPMI 1640 containing 10% FCS and cultured in the presence of 1% PHA (Wellcome, Beckenham, UK). To investigate the effects of factor VIlI concentrates on IL-2 secretion, the cultures were incubated with or without the appropriate factor VI11 concentrate in flat-sided tubes. Control cultures in the absence of PHA were included in each assay. The supernatants were harvested after 18 to 24 hours of culture from Jurkat cells, and after 40 hours from PBMC cultures. All supernatants were frozen at -20°C until assayed for IL-2.
Antibody to human TGF-PI. This antibody was generated by immunization of white leghorn chickens with recombinant human (rh) TGF-P1 using the immunization schedule described elsewhere." The antibody purified from egg yolk by the dextran sulfate rneth~d,".'~ was specific for TGF-PI, the isoform of TGF-P abundant in platelets, lymphocytes, and monocytes. At a dilution of 1 :200 1-15 pg/mL IgY), the antibody was capable of neutralizing the biologic activity of 5 ng/mL of both recombinant DNA and plateletderived TGF-PI ."
In neutralization experiments, purified chicken anti-TGF-P1 (1:200 dilution) was incubated with the appropriate samples for 1 hour at 37°C before the addition of cells. Controls using the Ig derived from eggs of nonimmunized chickens were also included.
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From Bioassay for IL-2. IL-2 was measured using a bioassay based on the IL-2-dependent mouse cytotoxic lymphocyte cell line, CTLL-2." For this, 50 pL of cell suspension (5 X lo3 cells) was added to 50 pL of test samples or control medium, and cultured for 18 hours in 96-well microtiter plates. A titration of an IL-2 working standard calibrated directly against the World Health Organization First International Standard for human IL-2 (86/504) was included in each assay. The cultures were then pulsed for 4 hours with 3H-thymidine (0.5 pCi/well), harvested onto filter mats, and the radioactivity incorporated into DNA estimated by scintillation counting. The percentage inhibition was calculated using parallel-line analysis." The proliferation of CTLL-2 cells was unaffected by the presence of factor VI11 concentrates."
Bioassay for TGF-P. TGF-P was measured using a bioassay based on the ability of TGF-P to inhibit IL-5-induced proliferation of the erythroleukemic cell line, T F -l . * O For this, a dilution series of samples, ie, factor VI11 concentrates or TGF-P1 standard, was prepared in 100-pL volumes in 96-well microtiter plates. TF-I cells were washed three times, resuspended to lo5 cells/mL in RPM1 1640 containing 5% FCS and 10 ndmL IL-5, and 100-pL aliquots added to each well. The plates were incubated for 48 hours, pulsed for 4 hours with 'H-thymidine, harvested onto filter mats, and the radioactivity incorporated into DNA estimated by liquid scintillation counting. A dose-response curve of cpm versus dilution of standard or unknown was plotted, and the amounts of TGF-P in the samples estimated by comparison of the sample dilution series to the standard curve, using parallel-line analysis."
Activation of TGF-P in factor VIII concentrates. In biologic samples, a large proportion of TGF-P is often present in a latent form." Conversion to the active form is necessq if total TGF-P levels are to be estimated. Factor VI11 concentrates were activated by addition of 10 pL of 1.2N HCI to a 100-pL aliquot of the sample. The samples were mixed thoroughly, incubated at room temperature for 15 minutes, and neutralized by addition of 25 pL of 0.5-molL HEPES/0.72-moVL NaOH. The activated samples were then assayed at appropriate dilutions.
Fractionation of factor VIII concentrates. Intermediate-purity factor VI11 concentrates were fractionated using Sepharose CL-4B (Pharmacia, St Albans, UK), as described previously." The fractions were monitored for absorbance at 280 nm, and for inhibitory effects on IL-2 secretion by Jurkat cells. In addition, the fractions were assayed for the presence of TGF-P. In some experiments, the fractions were acid-activated for quantitation of total TGF-P levels. e l k c t on cytokinc-induced proliferation of the erythrolcakcrrlic cell line TF-I. This cell line proliferates in response t o GM-CSF, interleukin-3 ( I L 3 ) , IL-4, 1L-S, and the stimulatory activity 01' the latter two (but not the former two) cytokincs is susceptible t o inhibition by 'I'GF-0." Factor V l l l concentratcs did not downmodulate the GM-CISF or 1L-3 cffecls, but the 1L4-or IL-5-stimulated prolil'eration of TF-I cells was signilicmtly inhihitcd by some concentrates. A dose-response curve of' Il,-S-induced proliferation olTF-I cells, and inhibition o f ' this proliferation with the addition o f two different factor VI11 concentrates is shown in Fig I A and B.
RESULTS

IdentiJication and characterization of TGF-p as an inhibi
The above suggests that the inhibitory component o f factor V l I l concentraks Inxy be TCF-p and, to confirm this, WC L I S C~ ;I neutrali/.ing polyclonal antibody specitic for TGF-,OI."'This antibody W;IS able to reverse the inhibitory effcct of factor VIll concentrates on IL-S-induced prolifcration o T TF-l cells cithcr completely or partially, depending on the concentrate used (Fig I A and B) , whereas nonirntnune chicken egg IgY had n o cl'fecl (data not shown). This suggated that thc inhibitory cl'lect o f fllctor Vlll concentrates could be, at least partially, attributed t o the prcscnce o f TGFfl I i n thew products. For less than 0.5 pg/mL of TGF-P, and recognizes different recombinant forms, as well as the natural protein derived from human and bovine platelets." A typical dose-response curve of TGF-P1 and a factor VI11 concentrate causing inhibition of IL-5-induced proliferation is shown in Fig 2A and B , respectively. Results showed that concentrates that exerted significant inhibition of IL-2 secretion using Jurkat cells and IL-5 -induced proliferation of erythroleukemic cells also contained relatively large amounts of TGF-P. Intermediatepurity concentrates contained either intermediate or very low levels of TGF-0, depending on the product. All chromatographically purified concentrates contained detectable levels of TGF-P; some contained higher levels than intermediatepurity products (Table 1 ). The very-high-purity noninhibitory concentrates prepared by monoclonal antibody affinity purification contained no detectable TGF-P ( Table 1) . The ability of concentrates to inhibit IL-2 secretion correlated with the TGF-P content of the concentrates (Fig 3) . The correlation coefficient of the two variables using Spearman rank correlation was 0.804 for total TGF-P and 0.829 for active TGF-P, taking each observation as an independent result (in both cases, P = .0001). Product G caused appreciable inhibition of L -2 secretion, but contained no detectable active TGF-P. However, this concentrate contained a significant amount of latent TGF-P, which may become active during cell culture and induce inhibition of IL-2 secretion.
Reversal of inhibitory effect of some factor VIII concentrates on IL-2 secretion from stimulated Jurkat cells or PBMCs by antibody spec@ for TGF-PI. To determine if TGF-01 in the concentrates was responsible for the inhibitory effects of concentrates on IL-2 secretion from stimulated Jurkat cell^,'*^'^ a neutralizing antibody against TGF-P1 was included in experiments involving either Jurkat cells or PBMCs. The TGF-P1 antibody neutralized the inhibitory effect of factor VI11 concentrates in a dose-dependent manner (Fig 4) .
Addition of the TGF-P1 antibody abrogated almost all of the inhibition exerted by product A at 2.5 IU/mL on IL-2 secretion from stimulated Jurkat cells (Fig 5) . However, with products C and D at 2.5 to 3 IU/mL, only 5% to 30% of the inhibitory activity was removed; these products required further dilution to either 1.25 IU/mL or even 0.625 IU/mL to obtain complete neutralization. Almost all inhibitory activity observed with products C and D at concentrations of 0.625 IU/mL in the IL-2 secretion Jurkat cell system was abolished in the presence of the TGF-01 antibody (Fig 6A and B) , while the nonimmune chicken egg IgY had no effect (Fig  6C) . These products contained large amounts of TGF-Dl, as determined by bioassay (Table l) , and also caused total inhibition of IL-2 secretion. With high-purity products, 30% to 50% of the inhibitory activity was removed by the TGF@l antibody, despite a comparable or even higher TGF-P1 content in these products relative to some intermediate-purity products. The amount of antibody required for neutralization of the inhibitory activity of TGF-P1 varied between products. As expected, there was no effect of the antibody on IL-2 secretion in the presence of noninhibitory concentrates, J and K (Fig 5) . These results provide evidence for TGF- P1 as a component responsible for the inhibitory effect of concentrates on IL-2 secretion from stimulated T cells.
IL-2 secretion inhibition experiments with factor VI11 concentrates in conjunction with the neutralizing antibody to TGF-P1 were also performed using PBMCs. As with Jurkat cells, the addition of neutralizing antibody reversed the inhibitory potential of some factor VI11 concentrates on IL-2 secretion by PHA-stimulated PBMCs (data not shown). As expected, the nonimmune chicken egg IgY did not reverse the inhibitory effect of the concentrates.
Inhibition of IL-2 secretion from Jurkat cells by spiking a noninhibitory factor VIII concentrate with active human TGF-PI. PHA-stimulated Jurkat cells were incubated with an affinity-purified noninhibitory concentrate in the presence or absence of different concentrations of rhTGF-P l . While the concentrate itself was noninhibitory, exogenous addition of TGF-P1 induced an inhibition profile similar to that obtained using TGF-01 alone as a control (Fig 7) . These results illustrate that addition of TGF-P1 to a previously noninhibitory factor VI11 concentrate mimics the inhibition of IL-2 secretion exhibited by inhibitory factor VI11 products.
Inhibitory fractions from factor VIII concentrate contain TGF-PI. Having identified TGF-/3 as a contaminant of some factor VI11 concentrates, gel-filtration analysis was used to establish the molecular form(s) of the cytokine present and the relationship of these with the substances responsible for inhibition of IL-2 secretion from T cells. The protein profile of an intermediate-purity factor VI11 concentrate C is shown in Fig 8A. As previously ~h o w n , '~ evaluation of the fractions for effect on IL-2 secretion from Jurkat cells indicated a major peak (fraction 50) of inhibition at approximately 200 k D , and a minor peak (fraction 77) at a molecular weight of approximately 60
These fractions, as well as a noninhibitory fraction, were acid-activated and tested, both in the presence or absence of the TGF-P1 specific antibody for effect on L 2 secretion. Both peaks contained inhibitory activity, which was significantly neutralized by the TGF-P1 specific antibody and contained significant amounts of TGF-P. Following acid activation, the biologic activity was substantially increased, and was neutralized by the antibody to TGFPl, confirming the presence of TGF-P1 in both fractions ( Fig   8B) . The noninhibitory fraction contained no detectable TGF-P (data not shown). Therefore, it seems most likely that the 200") inhibitory peak contains latent TGF-P, whereas the 60-kD peak contains the cytokine complexed with some other plasma-derived cornponent(s) or self-aggregated TGF-P. proliferation, differentiation, or other aspects of cellular function." Three structurally and functionally related isoforms of TGF-0-01, 02, and P3"have been described in man. The 0 1 form is abundant in platelets, lymphocytes, and macrophages. TGF-0 is produced as a latent 210-to 235-kD complex. This is composed of a 135-kD modulator protein, a 75-kD dimeric latency-associated glycoprotein derived from the TGF-p precursor, and mature dimeric 25-kD TGF-p.23 This complex can be activated by transient exposure to extremes in pH, chaotropic agents, repeated freeze thawing, or proteases to yield the biologically active 25-kD dimer capable of binding to specific cell-surface receptors to cause the appropriate biologic action on the target cell.
DISCUSSION
TGF-/3 is a multifunctional polypeptide that influences a diverse range of cell types by either stimulating or inhibiting
TGF-0 is a potent immunomodulatory molecule exerting profound immunosuppressive effects. In vitro studies have shown that TGF-P inhibits proliferation of T lymphocytes,24 as well as secretion of some c y t o k i n e~.~~~~~ TGF-P exerts differential effects on CD4+ and CD8+ cells; it can almost completely inhibit cell-mediated immune functions of CD4+ but it is less inhibitory for CD8+ cells, and may even promote their growth2* It can also enhance secretion of some other cytokines, eg, IL-4 and interleukin-l0 (IL-lo), which, in turn, can exert immunosuppressive effects," either alone or in concert with TGF-0. TGF-/? also inhibits the generation of cytotoxic T lymph0cytes,2~ induction of IL-2-induced lymphokine-activated killer cell activity:' and interferongamma (y-IFN) augmentation of natural-killer cell^.^' Additionally, TGF-p inhibits the growth of B cells, and compromises their responsiveness to antigens by decreasing membrane immunoglobulin expression and the ability to secrete antibodies following IL-2-or IL-6-induced ~timulation.~~ This cytokine also exhibits diverse effects on monocytes, induces chemotaxi~?~ and enhances production of cytokines, such as IL-1, while impairing respiratory burst activity. 34 Our studies show that some factor VI11 concentrates diminished the proliferative response of "F-1 cells to IL-5. Addition of antihuman TGF-01 reversed this inhibitory effect, suggesting the presence of TGF-01 in the concentrates. Furthermore, the inhibitory effect of some concentrates on IL-2 secretion from stimulated Jurkat cells was completely or partially reversed in the presence of anti-TGF-01, providing further evidence for TGF-P1 in some concentrates. Some concentrates may contain biologically compromised degraded TGF-01 that binds the antibody or even other protein molecules, which impair the binding of TGF-01 to the antibody, and so more antibody is required to neutralize the biologic effects of TGF-/?l. We have previously shown that the inhibitory activity of concentrates involves more than hibitory activity removed by the TGF-P 1 antibody can vary between products, and also between batches, depending on the amounts of the different components in the concentrates. In some products, eg, those that were affinity-purified, there was no detectable TGF-P, while other concentrates contained substantial amounts of the cytokine sufficient to cause total inhibition of IL-2 secretion from T lymphocytes in the experimental systems used. Other concentrates contained intermediate amounts of TGF-0, which closely correlated with the ability of these products to inhibit IL-2 secretion from T cells. There was no obvious relationship between the levels of TGF-P in the concentrates and the purity of the products, as has been shown for inhibition of IL-2 secretion.12.'' In particular, levels of TGF-P in some of the chromatographically purified products were higher than in some intermediate-purity products, despite their much higher specific activity (Table 1) . The presence of TGF-P in both active and latent forms in the factor VI11 concentrates is perhaps not surprising. Human plasma is the starting material from which all the concentrates studied here are prepared, and may contain considerable amounts of TGF-P 1, predominantly derived from platelets, although lymphocytes and monocytes are also capable of secreting the cytokine. Handling of plasma and storage conditions before cryoprecipitation could cause lysis of the residual platelets in plasma and release of latent TGF-P, which on exposure to chemical andor thermal treatment for extraction and manufacture of the final product may yield biologically active TGF-P.
Some biologic effects mediated by TGF-P on cells of the immune system show resemblance to those observed in vitro following incubation with some factor VI11 concentrates. Inhibition of mitogen-induced lymphocyte proliferation and IL-2 impaired natural-killer cell activity, and impaired monocyte f~n c t i o n '~"~ have been documented. In hemophiliacs undergoing concentrate therapy, infusion of concentrates that contain considerable amounts of TGF-P may cause a transient impairment of IL-2 secretion and several other related effects, such as y-IFN production, inhibition of the activity of some cytokines, and inhibition of Band T-cell expansion, followed by a gradual normalization as TGF-P and induced substances are cleared from the blood. Pharmacokinetic studies in rats have shown that biologically active TGF-P1 is cleared from the circulation within minutes, but the latent form circulates with a half-life of more than 90 minutes.35 Although the physiologic mechanisms whereby TGF-P is activated in vivo are unknown, cleavage of the latent form by proteolytic enzymes may yield the active molecule, which in turn may induce yet another secondary episode of immunologic disturbance in hemophiliacs undergoing therapy. Aberrations in immune function, which can be induced by TGF-P, may contribute to the susceptibility of such patients to infection^.".^'
A marked depression of inflammatory and immunologic responses has been observed in animals systemically administered TGF-P1 for treatment of autoimmune diseases, such as experimental allergic encephalomyelitis.'8 In acquired immune deficiency syndrome (AIDS), endogenous overproduction has been implicated in the development of immunodeficiency.'y.m Kekow et al" have shown that defective responses of CD4+ lymphocytes to the recall antigens purified protein derivative or tetanus toxoid were partially restored on addition of antibody to TGF-P in PBMC cultures from HIV-infected donors. Furthermore, purified TGF-P or PBMC culture supernatant (containing TGF-P) from HIVpositive individuals preferentially inhibited proliferation of CD4+ lymphocytes, as compared with CD8' cells. In HIVseropositive hemophiliacs, administration of concentrates that contain high levels of TGF-P (eg, some intermediatepurity and conventional high-purity) could exacerbate the disease and alter the clinical outcome. There is some evidence for this from recent clinical studies, showing a decline in CD4' counts in patients given some intermediate-purity or conventional high-purity products, but not in patients treated with monoclonal antibody affinity-purified product^.^"^' Our results clearly show significant variation between products, even within the same purity groups with respect to TGF-P content or inhibition of IL-2 secretion by T cells. Thus, conclusions cannot be drawn concerning inhibitory effects of products of a specific purity group from results with one particular factor VI11 concentrate.
